,	13	10 %	PT Approved for use through 09/30/2000 O	O/SB/05 (3-01)
Please type a plus sign (+) inside this box → +			Patent and Trademark Office U.S. DEPARTMENT OF	
	Attorney Docke	t No.	PC10856A	
UTILITY PATENT APPLICATION	First Inventor		Juan Colberg	
TRANSMITTAL	Title		PROCESS AND ESTER DERIVATIVES USEFUL FOR PREPARATION OF CEPHALOSPORINS	
Only for new nonepplications under 37C F.R. §1.53(b))	Express Mail L	abel No.		P 2
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application	contents.	AD.	DRESS TO: Commissioner for Patents Box Patent Application Washington, DC 20231	.8579
Fee Transmittal Form (e.g., PTO/SB/1: (Submit an original, and a duplicate for fee processi Applicant claims small entity status	7)	7	CD-ROM or CD-R in duplicate, large table or computer Program (Appendix) cleotide and/or Amino Acid Sequence Submission applicable, all necessary)	11,002 U. 10/00
See 37 CFR 1.27 Specification [Total Pages (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applics - Statement Regarding Fed sponsoret - Reference to sequence listing, a babl or a computer program listing a babl	d R&D le,		a. Computer Readable Copy (CRF) b. Specification Sequence Listing on:	copies
 Background of the Invention 			ACCOMPANYING APPLICATION PART	S
Brief Summary of the Invention Brief Description of the Drawings (if Detailed Description Claim(s) Abstract of the Disclosure	filed)	9.	Assignment Papers (cover sheet & document 37 CFR 3 73(b) Statement (when there is an assignee)	(s)) of Attorney
, 553,451, 515 2153,222		11.	English Translation Document (if applicable)	
4. Drawing(s) (35 U.S.C. 113) [Total sheet	s]	12.	Information Disclosure Copies Statement (IDS)/PTO-1449 Citatio	s of IDS ns
Oath or Declaration [Total page	s 🔲]	13.	Preliminary Amendment	
a. Newly executed (original or co		14.	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
(for continuation/divisional with Box	18 completed)	15.	Certified Copy of Priority Document(s) (if foreign priority is claimed)	
Signed statement attached deletin named in the prior application, se 1.63(d)(2) and 1.33(b).	ng inventor(s)	16.	Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/s or its equivalent.	

If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.

6.. Application Data Sheet. See 37 CFR 1.76

Continuation-in-part (CIP) Divisional of prior application No: _ Continuation Prior application information: Examiner Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 8b is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relieful upon when a perior has been individently only and from the submitted application part.

Other:

18. CORRESPONDENCE ADDRESS (Insert Customer No. or Attach bar code label here) or Correspondence address below Customer Number or Bar Code Label

23913 Name Address State Zip Code City

Telephone Country Registration No. (Attorney/Agent) 45,963 NAME (Print/type) Elsa Diuardi 12/4/01 Signature Gleade Date

PTO/SB/17(11-00) Approved for use through 10/31//2002 OMB 0651-0032 U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE to a collection of information unles it displays a valid OMB control number. Under the Paperwork reduction Act of 1995, no persons are required to respond to a Complete if Known Unassigned Application Number FEE TRANSMITTAL Concurrent herewith For FY 2001 Filing Date Juan Colberg First Named Inventor Unassigned Examiner Name Unassigned Patent Fees are subject to annual Revision Group/Art Unit (\$)1,334.00 PC10856A Total Amount of Payment Attorney Docket No. FEE CALCULATION (continued) METHOD OF PAYMENT The commissioner is hereby authorized to charge 3. ADDITIONAL FEES 1. 🛛 idicated fees and credit any over payments to 16-1445 Deposit Fee Paid Small Fee Description Entity Number Code Fee Fee (2) 105 130 205 65 Surcharge - late fee or oath Pfizer Inc Deposit Account Name Surcharge-late filing fee or cover sheet 127 227 Charge Any Additional Fee Required Under 37 CFR 1 16 and 1 17 130 130 139 130 Non-English specification Applicant claims small entity status. 147 2.520 147 2 520 For filing a request for ex parte rexamination See 37 CFR 1 27 920 112 920 112 Requesting publication of SIR prior to Payment Enclosed: 2. Examiner action 1,840* 113 1,840 Requesting publication of SIR after Credit card Money Order Other 113 Check Examiner action 55 115 110 215 **FEE CALCULATION** 400 216 200 Extension for reply within second month 116 1. BASIC FILING FEE 460 117 920 217 Extension for reply within third month Large Entity **Small Entity** Fee Paid 118 1,440 218 720 Extension for reply within fourth month Fee Description Fee Code Fee (5) (\$) Code 1.960 228 980 128 Extension for reply within fifth month 740 101 740 201 355 Utility filing fee 119 320 219 160 Notice of Appeal 206 165 Design filling fee 106 330 160 120 320 220 Filing a brief in support of an appeal 255 Plant filing fee 510 207 107 121 280 221 140 Request for oral hearing 370 Reissue filing fee 108 740 208 138 1,510 138 1.510 Petition to institute a public use proceeding 214 80 filing fee 240 55 110 740 140 SUBTOTAL (1) (\$) 241 640 141 1,280 Petition to revive - unintentional 2. EXTRA CLAIM FEES 1.280 242 640 Utility issue fee (or reissue) Fee from Extra Claims 243 230 18 342 143 460 Design issue fee 19 х -20**= Total Claims 244 310 3 252 144 620 Plant issue fee 6 - 3**= Independent 122 130 122 130 Petitions to the Commissioner 0 Multiple Dependent 123 50 Processing fee under 37 CFR 1 17(q) 123 50 Large Entity Small Entity 126 180 180 Submission of Information Disclosure Stmt Fee Fee Eee Description 126 code 581 40 581 40 Recording each patent assignment per property (times number of properties) 103 18 203 9 Claims in excess of 20 146 740 246 370 Filing a submission after final rejection 202 42 Independent claims in excess of 3 (37 CFR 1 129(a)) 149 740 249 370 For each additional invention to be 280 204 Multiple dependent claim, if not paid 104 examined (37 CFR § 1 129(b)) 179 710 279 355 Request for Continued Examination(RCE) 80 209 42 **Reissue independent claims 109 over original patent 169 900 169 900 Request for expedited examination of a 110 18 210 **Reissue claims in excess of 20 design application and over original pater Other (specify) SUBTOTAL (2) (\$) 594

SUBMITTED BY			Complete (if applicable)		
Type or Printed Name	Elsa Djuardi	Registration No (Attorney/Agent)	45,963 .	Telephone	
Signature	Gleaden	(Attorney/Agenty		Date 12/4/01	

*Reduced by Basic Filing Fee Pald

** or number previously paid, if greater; For Reissues, see above

Subtotal (3)

CERTIFICATE OF MAILING - EXPRESS MAIL

PFIZER DOCKET NO: PC10856A					
APPLICATION NUMBER: N/A					
TITLE: : PROCESS AND ESTER DERIVATIVES USEFUL FOR PREPARATION OF CEPHALOSPORINS					
APPLICANT: Juan C. COLBERG et al					
"Express Mail" mailing label number EL874867466 US					
Date of Deposit December 4, 2001					
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box Patent Application, Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231.					
Michelle Dungee					
(Typed or printed name of person mailing paper or fee)					
A in the second					

(Signature of person mailing paper or fee)

Pfizer, Inc Patent Department, 20th Floor 235 East 42nd Street New York, NY 10017-5755